Enanta Pharmaceuticals Inc., a Watertown-based drug developer, has entered into a collaboration deal with Swiss giant Novartis for the development of a hepatitis C virus drug that could be worth as much as $440 million to Enanta.
Novartis will pay Enanta $36 million up front, according to a release, and could pay as much as $404 million more if Enanta hits certain clinical, regulatory, and commercial milestones. The deal is for Enanta’s lead development candidate to come out of its NS5A hepatitis C virus (HCV) inhibitor program, a compound called EDP-239. The drug candidate targets the non-structural 5A (NS5A) protein encoded by the hepatitis C virus, which is indicated as being vital to the virus’ replication among cells.
Read more....
0 comments:
Post a Comment